key: cord-0720147-wp0xey7p authors: Singh, Vasvi; Choi, Andrew D.; Leipsic, Jonathon; Aghayev, Ayaz; Earls, James P.; Blanke, Philipp; Steigner, Michael; Shaw Phd, Leslee J.; Di Carli, Marcelo F.; Villines, Todd C.; Blankstein, Ron title: Use of Cardiac CT Amidst the COVID-19 Pandemic and Beyond: North American Perspective date: 2020-11-13 journal: J Cardiovasc Comput Tomogr DOI: 10.1016/j.jcct.2020.11.004 sha: 94c9485c82134df0a06181209728207212d4fa26 doc_id: 720147 cord_uid: wp0xey7p The COVID-19 pandemic has affected patient care deliver throughout the world, resulting in a greater emphasis on efficiently and safety. In this article, we discuss the experiences of several North American centers in utilizing cardiac CT during the pandemic. We also provide a case-based overview which highlights the advantages of cardiac CT in evaluating the following scenarios: (1) patients with possible myocardial injury versus myocardial infarction; (2) patients with acute chest pain ; (3) patients with stable chest pain; (4) patients with possible intracardiac thrombus; (5) patients with valvular heart disease. For each scenario, we also provide an overview of various societies recommendations which have highlighted the use of cardiac CT during different phases of the COVID-18 pandemic. We hope that the advantages of cardiac CT that have been realized during the pandemic can help promote wider adoption of this technique and improved coverage and payment by payors. In keeping with the objective of balancing safety with effective healthcare delivery, the cardiovascular (CV) imaging program at Brigham and Women's Hospital (BWH) deferred all elective imaging studies in stable patients in mid-March 2020, until June 2020 when the peak of the initial surge of COVID-19 cases had passed. During this time non-elective cases such as coronary CTA in patients with unstable chest pain or coronary CTA in selected patients with non ST-elevation myocardial infarction continued. In addition, cardiac CT was performed without J o u r n a l P r e -p r o o f delay for patients who required planning prior to urgent cardiac procedures, including transcatheter aortic valve replacement (TAVR) and transcatheter mitral valve replacement (TMVR) cases, as well as cardioversion, or atrial and ventricular ablation procedures. During the pandemic, coronary CTA emerged as a useful test for COVID-19 patients who had elevated cardiac troponin levels in whom the etiology was unclear, and coronary CTA was used in selected cases to avoid invasive coronary angiography (ICA) (See Figure 1 for example). Due to the increased off-hours demand for evaluating such urgent cases, our coronary CTA service was temporarily made available 7 days a week. The coronary CTA protocol that was used for such urgent cases included a multiphase acquisition to evaluate for left and right ventricular systolic function and regional wall motion abnormalities. In addition, a full chest CT was also performed at the same time, in cases where this information was felt to be useful by the clinical team. Because our COVID-19 coronary CTA cases were performed off-hours, we instituted the use of nitroglycerin patches (instead of sublingual tablets). The advantages of using patches was that they could be placed by the emergency room or inpatient team prior to the patient arriving in the CT room (where physicians were not present off hours). Another important change was to our cardiac CT program related to education of trainees. To promote social distancing, we minimized the number of individuals in our reading room, and reading sessions and cardiac CT conferences were all performed virtually using Microsoft Teams, in keeping with all other educational activities in the hospital. Our "virtual reading room" was also made available to all referring clinicians in order to allow them to join if they were interested in reviewing any studies, or to ask any questions related to cardiac CT. In J o u r n a l P r e -p r o o f addition, our BWH faculty and fellows participated in international teaching sessions and webinars organized by the Society of Cardiovascular Computed Tomography (SCCT). Shortly following the onset of the COVID-19 pandemic in March 2020 the University of Virginia cardiac CT program deferred most elective studies until after the peak of the pandemic. Outpatients that were previously scheduled to be scanned were referred to the imaging team for review of the clinical information and study indications. Patients deemed to not to have an urgent need for study performance were the majority and the referring provider was contacted to let them know that the patient was going to be rescheduled to a later date. Referring providers were provided the opportunity to discuss patients that they felt should not be delayed and these patients were scheduled on a case-by-case basis, with most elective procedures ultimately being rescheduled. In patients with acute presentations, such as non-ST elevation acute coronary syndrome or newly decreased left ventricular systolic function, the utilization of coronary CTA increased. While coronary CTA was routinely performed for these indications, the interest and enthusiasm to order coronary CTAs by Emergency Department providers and among our interventional and non-imaging colleagues increased substantially. Furthermore, during this time, exercise testing had virtually ceased and the performance of pharmacologic stress imaging studies that required longer patient-staff exposure time, such as stress cardiovascular magnetic resonance (CMR) or nuclear modalities, were generally not available. Even in patients with low-risk non-ST segment elevation MI presentations, a population not typically referred for coronary CTA, we shifted to J o u r n a l P r e -p r o o f selective utilization of coronary CTA in lieu of ICA, many times at the request of our interventional cardiology colleagues. Finally, in patients with an urgent need for surgical valve intervention, coronary CTA quickly became the default study to evaluate for coronary artery disease. While coronary CTA had been previously performed in many such low risk patients, providers quickly realized the value and high diagnostic accuracy in higher risk patients without known coronary artery disease. The COVID-19 pandemic also significantly and permanently changed our utilization of transesophageal echocardiography (TEE) to evaluate for left atrial appendage thrombus prior to cardioversion procedures in patients with atrial fibrillation or atrial flutter. In March, the performance of TEE for this indication virtually ceased except for patients with advanced kidney disease or those who needed TEE for valvular interrogation. Interestingly, this shift has persisted with cardiac CT now serving as the default test for this indication at our institution. As the COVID-19 pandemic descended upon us in March our lab in Vancouver was faced with similar but also some unique challenges. Cardiac CT has grown rapidly over the last decade in Vancouver, and it is the primary modality for the evaluation of symptomatic patients with suspected but not yet confirmed coronary disease. This is in addition to the central role cardiac CT has been playing for years for acute chest pain as well as for structural heart disease planning. The demand for cardiac CT has outstripped our supply which is a reality that would be hard to imagine in other health care systems but is not uncommon in our capitated healthcare system. Given that with COVID-19 we could not afford to stop outpatient cardiac CT testing J o u r n a l P r e -p r o o f given the pre-existing waitlist and attempted to re-triage the requisitions focusing on those with compelling symptoms and positive or equivocal ECG treadmills. Our daily case volume was reduced from 25 to 15 through patient selection and also owing to requirements for spacing and enhanced cleaning protocols. Through the pandemic we continued to use non-invasive physiology with FFRct to guide medical and revascularization management in patients with anatomical CAD. This approach proved to be particularly effective and safe during COVID-19 as it provides physiology without having to bring the patient back to the hospital for additional testing. Beyond stable chest pain, for patients with acute chest pain we have been using coronary CTA to evaluate patients with indeterminate high sensitivity troponin levels. Early on in the pandemic, in particular when there was significant concerns regarding PPE supply, the use of coronary CTA extended to include many patients who would have historically proceeded for ICA. The clinical utility of this approach was meaningful, perhaps not surprisingly so, as the push to reserve an invasive approach for those requiring revascularization gained further momentum in this pandemic. As well, our efforts to explore coronary CTA in order to help avoid pre-TAVR ICA has seen increased interest with the declining anatomical disease burden with decreasing surgical risk making coronary CTA a viable option for more patients. With COVID we have seen growing demand for expanding the role of coronary CTA in this population to help expedite the work up of these patients and get them to their definitive therapy as quickly and safely as possible. To that end, we have begun optimizing acquisition protocols for coronary CTA in selected patients where safe and feasible to enable more robust coronary evaluation beyond proximal coronary segments again exploring non-invasive physiology (FFRct). These J o u r n a l P r e -p r o o f changes to practice have continued as we have returned to our routine clinical volumes and while predictions are difficult it would seem that COVID-19 has served as a crucible for change and its impact on coronary CTA usage will likely remain well after the pandemic subsides. The George Washington University Medical Center is an academic campus situated six blocks from the White House in Washington, DC. As the pandemic took hold in early 2020, our hospital entered into a state of full disaster preparedness with safety at the forefront of all care provisions. Since the first reported case of COVID-19 on March 7, 2020 in Washington, DC, cardiac CT has been a vital means to our care approach. Pre-pandemic, our institution had already shifted to a heart team model that In the midst of the pandemic peak, outpatient stable chest pain evaluation was triaged on a case by case basis and largely deferred. As COVID-19 cases have abated in our region, outpatient utilization of coronary CTA has increased as exercise stress testing has halted. Coronary CTA has often been preferred to pharmacologic stress testing approaches that require longer acquisition times and increased staff exposure; this approach is specifically reflected in our electronic medical record order set decision tree. The pandemic has created renewed interest from end-users of cardiac CT that include general internal medicine physicians who sought to better understand and utilize a safe, efficient approach to chest pain through coronary CTA that optimizes diagnosis, enhances cardiovascular prevention and aims to improve long-term outcomes. J o u r n a l P r e -p r o o f Throughout North America and around the world, the pandemic resulted in an estimated 50-90% decreased utilization of cardiovascular imaging tests, especially for imaging modalities that cause aerosolization of respiratory droplets such as transesophageal echocardiography (TEE) and exercise stress testing. 1 In addition, there was a significant decrease in the number of elective invasive coronary angiograms. In many centers, cardiac CT was used in place of such tests to provide a safer alternative and to conserve personal protective equipment (PPE). [2] [3] [4] [5] [6] [7] [8] Coronary CTA was also used to avoid inpatient admissions and expedite emergency room care among patients with acute chest pain. The following section will provide patient examples and a discussion of some of the key roles of cardiac CT during the pandemic. An York City hospitals identified a high prevalence of non-CAD related myocardial injury (n = 10 of 18). Similar experiences were also described throughout the United States. 10 The mechanism of COVID-19 induced myocardial injury is postulated to be multifactorial, with possible contributors which include plaque rupture, coronary artery spasm, coronary microthrombi, hypoxic injury, via a cytokine storm, or from direct endothelial injury. 11 While not routinely performed in all centers, another method to evaluate for myocarditis is by the use of CT delayed enhancement imaging. This technique often requires the administration of a larger dose of intravenous contrast, and acquiring an additional post contrast scan. 12 In the appropriate clinical setting, areas of subepicardial delayed enhancement can be useful for diagnosing myocarditis. 12 Cardiac CT is not recommended to evaluate patients with definitive ST elevation myocardial infarction. These patients should proceed directly for definitive therapy as per local institutional protocol. 13 In patients with equivocal symptoms and atypical ECG, joint decision making between the Emergency Department (ED) provider, imaging team and interventional cardiology team regarding coronary CTA or invasive angiography is recommended. 2, 8, 14 Figure 2 shows the BWH algorithm that was used during the COVID-19 pandemic. A 45 year old male healthcare worker with long standing uncontrolled hypertension (noncompliance to medications) presented with intermittent central chest pressure, nausea, myalgias, and subjective fever. Physical exam was notable for a high resting blood pressure of J o u r n a l P r e -p r o o f 180/90 mmHg. ECG in the Emergency Department (ED) was unremarkable and two serial TnThs were negative. His first COVID test was negative, and a second one was pending. The patient was referred for an expedited coronary CTA from the ED to elucidate the cause of his acute chest pain. Coronary CTA demonstrated no plaque or stenosis ( Figure 3A) . He was started on anti-hypertensive medications with improvement of symptoms, and discharged home after the second COVID test came back negative. A 59 year old female, current smoker, with prediabetes, obesity, and a family history of CAD presented with episodic epigastric pain for the past two weeks. Her physical exam and ECG were unremarkable in the ED. Two serial TnT-hs levels were within normal limits. An urgent coronary CTA ordered from the ED showed no coronary plaque or stenosis but revealed a moderate size hiatal hernia which was probably the cause for this patient's symptoms ( Figure 3B ). Coronary CTA is useful for evaluating patients with suspected acute coronary syndrome who do not have a prior history of CAD. To date, there have been five randomized trials of coronary CTA in the ED, all demonstrating the safety and efficiency of this technique. [18] [19] [20] [21] [22] Use of coronary CTA in the ER and observation unit setting has been shown to reduce the time to diagnosis, as well as length of stay. 23 Coronary CTA is also useful in identifying other etiologies of chest pain (e.g. aortic or pulmonary pathology and hiatal hernia). Patients with no plaque or stenosis on a coronary CTA have excellent prognosis, with a very low future risk of cardiac death or MI. 23 Conversely, patients who are diagnosed with CAD on coronary CTA are most J o u r n a l P r e -p r o o f likely to benefit from lifestyle and preventive pharmacologic treatment. In addition, coronary CTA has the ability to detect atherosclerosis and therefore impact patient management on a larger scale, although implementation of preventive therapies following CTA in the ED remain suboptimal. 24 The European Society of Cardiology (ESC) guidance for the diagnosis and management of CV disease during the pandemic advocates coronary CTA as the preferred noninvasive imaging modality in patients with acute chest pain and suspected significant CAD, due to its accuracy, short scan time and minimal exposure risk of patients and healthcare team. 25 A 58 year old male with distal esophageal cancer ( Figure 4A1 ) on chemoradiation was suffering from worsening dysphagia, and was planned for an expedited surgical esophagectomy. He had diabetes mellitus, hyperlipidemia and was also complaining of intermittent central chest pain that was sometimes relieved with sublingual nitroglycerin. A cardiac CT was ordered during the COVID-19 pandemic to evaluate for high risk coronary anatomy prior to emergent surgery, which showed only minimal stenosis (1-24%) of the mid LAD and the left circumflex (LCX) ( Figure 4A2) . The patient underwent a successful surgical esophagectomy within the next few days. A 72 year old female with newly diagnosed breast cancer was planned to be started on chemotherapy. A screening TTE prior to initiation of the chemotherapeutic regimen revealed moderately reduced LVEF, with no prior TTEs for comparison. Cardiac CT was ordered for J o u r n a l P r e -p r o o f assessment of significant CAD, that showed a small amount of calcified and non-calcified plaque resulting in minimal stenosis (1-24%) of the proximal LAD and mild stenosis (25-49%) of the mid LAD ( Figure 4B2 ). There was moderate biatrial enlargement, moderate LV cavity dilatation along with moderately reduced LV systolic function ( Figure 4B1) . Overall, the cardiac CT findings were consistent with a non-ischemic cardiomyopathy. The patient was started on optimal medical therapy for LV dysfunction and non-cardiotoxic chemotherapy was initiated. A 66 year old female with known CAD and recent coronary artery bypass graft (CABG) surgery presented with new onset dyspnea on exertion and heart failure. She was referred for a regadenoson myocardial perfusion positron emission tomography (PET) study that showed a dilated left ventricle with severe systolic dysfunction. There was a large reversible perfusion defect of moderate intensity involving the entire septum, associated with an abnormal interventricular septal motion ( Figure 5B ). Her ECG demonstrated a baseline left bundle branch block (LBBB) ( Figure 5A ). One plausible explanation for the stress induced septal perfusion defect would be related to LBBB. On the other hand, with a recent CABG including a left internal mammary artery (LIMA) bypass graft to LAD raised concern for LIMA graft occlusion. Coronary CTA demonstrated a patent LIMA to LAD and a patent saphenous venous graft to posterior descending artery along with known multivessel native CAD ( Figure 5C ). The patient was treated conservatively with medical therapy with good symptom control. The potential role of coronary CTA in selecting patients for treatment with aggressive medical therapy was demonstrated by the recent ISCHEMIA trial. Over a median follow-up period of 3.3 J o u r n a l P r e -p r o o f years, coronary revascularization did not reduce the risk of cardiovascular events in stable patients with symptomatic CAD and moderate to severe ischemia, when compared with optimal medical therapy. 26 This trial provided support that an initial treatment strategy using aggressive medical therapy was safe. In this study coronary CTA was used to rule out left main disease (~5% of patients) and patients who did not have obstructive CAD (~14% of patients) despite an abnormal functional study. However, in patients with angina, coronary revascularization led to a reduction in anginal symptoms and improved quality of life. In patients with significant symptoms and severe stenosis on coronary CTA, or in those with high risk coronary anatomy on coronary CTA (left main disease or multivessel CAD), coronary revascularization may be preferred. Therefore, in patients who demonstrate ischemia on functional testing, coronary CTA can be used to exclude high risk coronary anatomy, especially if a strategy of medical therapy alone is being pursued. 27,28 A 60 year old male with hypertension presented with episodes of chest pain, palpitations and nausea for several days. He was found to be in atrial fibrillation with rapid ventricular response. He was experiencing significant palpitations and intermittent episodes of chest pain. Labs showed mildly elevated hsTn levels of 45 and 50 ng/L. The first COVID-19 test was negative in the ED, and results from the second sample were pending. The patient was scheduled for an expedited cardioversion after ruling out a left atrial appendage thrombus. Considering all factors, a cardiac CT was ordered from the ED to evaluate for both significant CAD as a cause of J o u r n a l P r e -p r o o f his chest pain, and an intracardiac thrombus prior to cardioversion. Cardiac CT showed a small amount of non-calcified plaque resulting in mild stenosis (25-49%) of the mid LAD ( Figure 6A) , and also revealed a left atrial appendage thrombus, seen as a filling defect on both early ( Figure 6B ) and delayed contrast enhanced images ( Figure 6C ). The patient was started on high intensity statin therapy, rate control medications and anticoagulation. His symptoms improved with heart rate control and he was discharged from the ED after the second COVID-19 test returned negative. Cardiac CT has a high accuracy to exclude left atrial appendage thrombus with a sensitivity and NPV of nearly 100%, 29 when a delayed phase is also acquired. A filling defect in the left atrial appendage on early contrast enhanced images can represent stasis, and thus post-contrast delayed imaging may be necessary in such cases to confirm or exclude the presence of a clot. 30 TEE is an aerosol generating procedure considered by expert opinion and available evidence to be at high risk for potential spread of the virus through direct contact with patient secretions. The procedure also involves multiple team members including a physician, technologist, circulating nurse and anesthesiologist. 1, 31 In contrast, in the current scenario, cardiac CT enables reduced PPE use, decreased resource utilization, and enhanced safety to patients and health care workers. For this reason, in all of our institutions, cardiac CT was used in preference to TEE for excluding left atrial appendage thrombus. Figure 7A4 ). While not commonly observed, it has been shown that MAC is an inflammatory process that may serve as a nidus for infective endocarditis especially with staphylococcus aureus species due to mechanism of attachment, as demonstrated in this case with intense focal FDG uptake at the MAC location in a patient with sepsis of otherwise unknown source. 32 The patient was treated with a prolonged course of antibiotics and did well. Cardiac CT is an excellent alternative for evaluating patients with known or suspected infective endocarditis ( Figure 7B ), especially when an initial TTE is inconclusive, or when TEE is not feasible. A distinctive advantage of cardiac CT over echo is the ability to evaluate prosthetic valves ( Figure 7C ) 33 , and is suitable for detecting perivalvular involvement, including pseudoaneurysm ( Figure 7D ) or fistulas. Accordingly, the current ESC guidelines recommend J o u r n a l P r e -p r o o f the modified Duke Criteria where identification of paravalvular involvement by cardiac CT is a major criteria for the diagnosis of infective endocarditis. 34 A survey published in 2020 by the European Association of Cardiovascular Imaging reported that 60% of surveyed sites prepandemic were using cardiac CT for diagnostic purposes in infective endocarditis, most often in those patients with complex prosthetic valve endocarditis and in cases when TEE was inconclusive. 35 In addition to evaluation of endocarditis, cardiac CT continued to have an important role in evaluating patients prior to urgent transcatheter aortic valve replacement (TAVR) 33 or transcatheter mitral valve replacement (TMVR) 36 procedures. In addition, coronary CTA has become more widely used as part of these scans in order to evaluate for significant CAD and thus avoid additional diagnostic angiography procedures. 33 In summary, cardiac CT has been used in many roles during the COVID-19 pandemic ( Figure 8 ). [37] [38] [39] While the selective utilization of cardiac CT has proven to be vital to many North American Multimodality Cardiovascular Imaging in the Midst of the COVID-19 Pandemic: Ramping Up Safely to a New Normal Safe Reintroduction of Cardiovascular Services during the COVID-19 Pandemic: Guidance from North American Society Leadership Multimodality Cardiovascular Imaging in the Midst of the COVID-19 Pandemic: Ramping up Safely to a New Normal COVID-19 pandemic and cardiac imaging: EACVI recommendations on precautions, indications, prioritization, and protection for patients and healthcare personnel Guidance and best practices for nuclear cardiology laboratories during the coronavirus disease 2019 (COVID-19) pandemic: An Information Statement from ASNC and SNMMI ASE Statement on Protection of Patients and Echocardiography Service Providers During the 2019 Novel Coronavirus Outbreak: Endorsed by the American College of Cardiology Society for Cardiovascular Magnetic Resonance (SCMR) guidance for the practice of cardiovascular magnetic resonance during the COVID-19 pandemic Society of Cardiovascular Computed Tomography guidance for use of cardiac computed tomography amidst the COVID-19 pandemic Endorsed by the American College of Cardiology ST-Segment Elevation in Patients with Covid-19 -A Case Series Reduction in ST-Segment Elevation Cardiac Catheterization Laboratory Activations in the United States During COVID-19 Pandemic Myocardial localization of coronavirus in COVID-19 cardiogenic shock Quadruple Rule-Out" With Computed Tomography in a COVID-19 Patient With Equivocal Acute Coronary Syndrome Presentation Management of Acute Myocardial Infarction During the COVID-19 Pandemic: A Position Statement From the Society for Cardiovascular Angiography and Interventions (SCAI), the American College of Cardiology (ACC), and the American College of Emergency Physicians (ACEP) Management of Acute Myocardial Infarction During the COVID-19 Pandemic Coronary CT Angiography in Patients With Non-ST-Segment Elevation Acute Coronary Syndrome Initial Imaging-Guided Strategy Versus Routine Care in Patients With Non-ST-Segment Elevation Myocardial Infarction 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation Diagnostic accuracy of 64-slice computed tomography coronary angiography: a prospective, multicenter, multivendor study CT angiography for safe discharge of patients with possible acute coronary syndromes Coronary CT angiography versus standard evaluation in acute chest pain Diagnostic performance of computed tomography coronary angiography (from the Prospective National Multicenter Multivendor EVASCAN Study) Diagnostic performance of 64-multidetector row coronary computed tomographic angiography for evaluation of coronary artery stenosis in individuals without known coronary artery disease: results from the prospective multicenter ACCURACY (Assessment by Coronary Computed Tomographic Angiography of Individuals Undergoing Invasive Coronary Angiography) trial Meta-analysis of coronary CT angiography in the emergency department Preventive Management of Nonobstructive CAD After Coronary CT Angiography in the Emergency Department The European Society for Cardiology. ESC Guidance for the Diagnosis and Management of CV Disease during the COVID-19 Pandemic Initial Invasive or Conservative Strategy for Stable Coronary Disease Cardiac Imaging in the Post-ISCHEMIA Trial Era: A Multisociety Viewpoint Ischemia trial: Implications for coronary CT angiography Roles of Transesophageal Echocardiography and Cardiac Computed Tomography for Evaluation of Left Atrial Thrombus and Associated Pathology: A Review and Critical Analysis Detection of left atrial appendage thrombus by cardiac computed tomography in patients with atrial fibrillation: a meta-analysis Specific Considerations for the Protection of Patients and Echocardiography Service Providers When Performing Perioperative or Periprocedural Transesophageal Echocardiography during the Novel Coronavirus Outbreak: Council on Perioperative Echocardiography Supplement to the Statement of the American Society of Echocardiography Endorsed by the Society of Cardiovascular Anesthesiologists Mitral Annular Calcification as a Possible Nidus for Endocarditis: A Descriptive Series with Bacteriological Differences Noted Computed tomography imaging in the context of transcatheter aortic valve implantation (TAVI) / transcatheter aortic valve replacement (TAVR): An expert consensus document of the Society of Cardiovascular Computed Tomography ESC Guidelines for the management of infective endocarditis EACVI survey on the evaluation of infective endocarditis Use of Cardiac Computerized Tomography to Predict Neo-Left Ventricular Outflow Tract Obstruction Before Transcatheter Mitral Valve Replacement Myocardial injury in COVID-19: The role of coronary computed tomography angiography (CTA) Recommendations for risk stratified use of cardiac computed tomography for congenital heart disease during the COVID-19 pandemic Role of computed tomography in COVID-19 Multimodality Imaging in Evaluation of Cardiovascular Complications in Patients With COVID-19: JACC Scientific Expert Panel Current Evidence and Recommendations for Coronary CTA First in Evaluation of Stable Coronary Artery Disease J o u r n a l P r e -p r o o f • "Coronary CTA may be the preferred non-invasive imaging modality to diagnose CAD since it reduces the time of exposure of patients and personnel." • "Cardiac CT is preferred to TEE to rule out the presence of intracardiac thrombus." • "In patients with acute chest pain and suspected obstructive CAD, coronary CTA is the preferred non-invasive imaging modality since it is accurate, fast and minimizes the exposure of patients." • Stable NSTEMI patients: "Noninvasive imaging using coronary CTA may speed-up risk stratification, avoid an invasive approach allowing early discharge." • Myocarditis: "Coronary CTA should be the preferred approach to rule out concomitant CAD."